ESMO Breast 2020 and Trial Updates View overview page

3:05
Exploring the use of olaparib in advanced breast cancer
Gaia Griguolo • 21 May 2020
5:54
ROXANE: impact of 21-gene assay on treatment for early breast cancer
Maria Vittoria Dieci • 22 May 2020
4:09
TAXIS: tailored axillary surgery in clinically node-positive breast cancer
Walter Weber • 15 May 2020
6:46
SAFIR02-IMMUNO: PDL1 copy number changes predicts checkpoint blockade inhibitor efficacy in mBC
Thomas Bachelot • 22 May 2020
5:01
ShortHER study: validating the AJCC prognostic stage in HER2+ breast cancer
Maria Vittoria Dieci • 14 May 2020
7:09
Personalizing immunotherapy beyond PDL1 expression
Marleen Kok • 14 May 2020
3:29
Designing innovative clinical trials in BC
Giuseppe Curigliano • 18 May 2020
4:21
EMBRACA & OlympiAD: targeting DNA repair
Jennifer Litton • 7 May 2020
2:01
HER2CLIMB: tucatinib in combination w/ capecitabine & trastuzumab
Giuseppe Curigliano • 14 May 2020
2:43
CLEOPATRA & EMILIA: HER2+ mBC state-of-the-art
Sandra Swain • 7 May 2020
1:56
NSABP B-41: genes and signatures associated with pCR
Sandra Swain • 7 May 2020
2:40
CLEOPATRA: pertuzumab, trastuzumab & chemo for HER2+ mBC
Sandra Swain • 8 May 2020
5:45
Real-world: efficacy of everolimus + exemestane HR+, HER2- BC
Michael Gnant • 14 May 2020
3:53
GELATO: carboplatin and atezolizumab in advanced lobular BC
Leonie Voorwerk • 14 May 2020
4:19
The gut microbiome & triple negative breast cancer
Grazia Vernaci • 14 May 2020
4:11
Immunotherapy for TNBC: IMpassion130 & KEYNOTE-355
Sara Tolaney • 19 May 2020
The content of VJOncology is intended for healthcare professionals